Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report sent to investors on Thursday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

Several other brokerages have also recently weighed in on VYGR. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Wedbush reduced their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Finally, Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.43.

Voyager Therapeutics Trading Up 2.7 %

VYGR opened at $6.75 on Thursday. Voyager Therapeutics has a 1-year low of $5.71 and a 1-year high of $11.72. The company has a market cap of $367.16 million, a price-to-earnings ratio of -135.00 and a beta of 0.91. The company’s fifty day moving average price is $6.55 and its two-hundred day moving average price is $7.61.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.20. The business had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter last year, the firm earned ($0.51) EPS. As a group, equities analysts forecast that Voyager Therapeutics will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.53% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Large investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. boosted its holdings in Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after buying an additional 1,300 shares during the period. Plato Investment Management Ltd purchased a new stake in shares of Voyager Therapeutics during the first quarter worth $38,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after acquiring an additional 4,098 shares during the period. SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics in the second quarter valued at $85,000. Finally, ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics during the 1st quarter valued at $101,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.